<DOC>
	<DOCNO>NCT01689805</DOCNO>
	<brief_summary>Atopic dermatitis common disease affect one million people Finland stage life . In atopic dermatitis see superficial inflammation skin defect skin barrier function . The filaggrin protein play central role skin barrier function study indicate 30 % patient atopic dermatitis mutation filaggrin gene . The aim study investigate whether mutation filaggrin gene affect clinical treatment outcome patient atopic dermatitis . If mutation predispose bad response treatment , could examine patient mutation could give extra treatment support atopic dermatitis . The prevalence filaggrin mutation Finnish non-atopic population study control group .</brief_summary>
	<brief_title>Clinical Importance Filaggrin Gene Mutation Treatment Outcome Atopic Dermatitis</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<criteria>Inclusion Criteria ( patient atopic dermatitis ) : Age least 18 year Clinical diagnosis atopic dermatitis Need followup Skin Allergy Hospital Patient give sign informed consent participate study Patients parent grandparent Finnish origin Inclusion Criteria ( Controls ) : No history atopy skin disease Age least 18 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Atopic dermatitis</keyword>
	<keyword>Filaggrin</keyword>
</DOC>